2010-07-05 3822
On November 7th to 9th, the "4th China Growth-oriented Pharmaceutical Enterprise Development Forum" organized by the Committee of China Growth-oriented Pharmaceutical Enterprise Development was grandly held at the Great Hall of the People in Beijing.
Government leaders and industry experts from various government agencies, including Huang Mengfu, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference, Song Beibin, Party Secretary of the All-China Federation of Industry and Commerce, Wang Delong, President of the Chinese Preventive Medicine Association, and She Jing, Director of the National Administration of Traditional Chinese Medicine, as well as entrepreneurs from growth-oriented pharmaceutical companies from all over the country such as Beijing Pharmaceutical Group, Shanghai Pharmaceutical Group, and Shanghai Fosun Pharmaceutical Group, totaling more than 600 people, attended the three-day forum.
The theme of this forum was "Seizing Opportunities, Building a Scientific Development Platform for Growth-oriented Pharmaceutical Enterprises." It focused on discussing the mainstream trends of market changes and industry development under the backdrop of the new healthcare reform, as well as the coping strategies of growth-oriented pharmaceutical enterprises. It also emphasized the research on the market expansion brought about by increased financial investment by the government, as well as the implementation of the essential drug system that followed.
During the forum, various speakers delivered speeches on topics such as "Lifestyle Revolution" by Wang Delong, President of the Chinese Preventive Medicine Association, "Pharmaceutical Production and Sales Models and Basic Drug Policies" by Yu Mingde, President of the China Pharmaceutical Enterprises Management Association, "The Road to Pharmaceutical Innovation" by Liu Changxiao, Academician of the Chinese Academy of Engineering, "China's Basic Drug System" by Xie Xiaoyu, Director of the System Division of the Department of Drug Policy and Basic Drug System of the Ministry of Health, "The Impact of Obama's Healthcare Policy on Chinese Enterprises" by Dr. Marc J. Scheineson from the U.S. FDA, "Development and Research of Traditional Chinese Medicine in Hong Kong" by Xu Hongxi, Deputy Director of the Chinese Medicine Research Institute of the Hong Kong Jockey Club, and "Buddhist Lecture Hall - Buddhist Wisdom and Entrepreneurial Management" by Master Zhizong, Abbot of Shuangquan Monastery on Putuo Mountain. Additionally, entrepreneurs such as Ren Fulong, Chairman of Shandong Xinhua Pharmaceutical, and Si Tingyou, General Manager of Nick Meikang Pharmaceutical in China, gave speeches on industry-related topics.
During the forum, more than 600 representatives jointly issued the "Beijing Communique of the 4th China Growth-oriented Pharmaceutical Enterprise Development Forum." The "Communique" pointed out that after years of tempering, China's growth-oriented pharmaceutical enterprises have grown and become an indispensable force in the Chinese pharmaceutical industry, highlighting their significant economic and social value. During the current period of transformation in the pharmaceutical industry, growth-oriented pharmaceutical enterprises should actively embrace the industrial transformation and changes driven by the implementation of the new healthcare reform, grasp, analyze, and follow the mainstream, seize the opportunity of healthcare reform, change their mindset and approaches, formulate medium- and long-term development plans, and achieve faster and greater development.
The "Communique" unanimously recognized that "grasping the new healthcare reform opportunities, accelerating technological innovation, and promoting the scientific development of enterprises" is the fundamental growth path for growth-oriented pharmaceutical enterprises. It advocated relying on national industrial policies, market orientation, enterprises as the main body, products as carriers, core technology as the focus, system as the guarantee, and people-oriented principles to construct a technological innovation system for growth-oriented pharmaceutical enterprises. It also called for increased investment in scientific research, consolidation and promotion of industry-university-research cooperation, strengthening basic research, applied basic research, and development research, continuously developing products with independent intellectual property rights, and vigorously cultivating and enhancing the core competitiveness of enterprises.
The China Growth-oriented Pharmaceutical Enterprise Development Forum is an industry organization initiated and established by companies such as Guangdong Yangjiang Pharmaceutical, Zhejiang Weikang Pharmaceutical, and Guangdong Fuda Pharmaceutical in 2006. The organization aims to "communicate, cooperate, develop, and win together" and currently has hundreds of pharmaceutical business and retail enterprise members. Previously, the first, second, and third forums were held in Hangzhou, Beijing, and Zhuhai in November 2006, November 2007, and October 2008 respectively. Over 1,800 growth-oriented pharmaceutical entrepreneurs participated in the previous three forums, and the "Hangzhou Declaration," "Beijing Initiative," and "Quality Declaration" were successively issued.